OSAKA-GAS
3.8.2022 04:02:06 CEST | Business Wire | Press release
Daigas Gas and Power Solution Co., Ltd. (“DGPS”), a 100% subsidiary of Osaka Gas Co., Ltd. (TOKYO: 9532), has established an expanded business collaboration for onsite hydrogen generator technology with Hyundai Rotem Company (“HRC”), an affiliate of Hyundai Motor Group, allowing HRC to sell the generators outside South Korea.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005489/en/
Daigas Group (formerly Osaka Gas Group) launched the first model of “HYSERVE” (*1) , onsite hydrogen generator, in 2003 by adopting its accumulated knowledge on catalyst. DGPS introduced a new model “HYSERVE-300” with hourly hydrogen production capacity of 300 Nm3 in 2013. DGPS, as manufacturer of HYSERVE-300, has sold the units mainly to hydrogen fueling stations.
Then in 2019, DGPS granted HRC to manufacture and sell “Hy-Green”, hydrogen generator utilizing the technology of HYSERVE-300, enabling HRC to meet the increasing demand for hydrogen fueling stations in South Korea.
After confirming HRC’s successful launch of Hy-Green, DGPS has decided to globally deploy its HYSERVE technology through enabling HRC to sell Hy-Green outside of South Korea. DGPS believes this will contribute the prompt buildup of distributed hydrogen supply infrastructure which is necessary for the decarbonization in transportation sector.
Hy-Green will be sold by HRC for the on-site hydrogen fueling station for various hydrogen mobilities (small vehicles, buses, trucks, construction equipment, train, ships, drones and etc), fuel cell power plant, and biogas production facilities (to produce hydrogen) in order to expand the hydrogen supply chain.
HRC has already developed mass production capacity of Hy-Green and is ready for receiving inquiries from the world including those through Daigas Group.
Daigas Group including DGPS is going to expand its overseas energy business from upstream to downstream by fully utilizing its experiences in and out of Japan and its existing overseas business platforms.
(*1) |
Onsite hydrogen generator developed and sold by Daigas Group. 36 units have been sold in Japan so far. |
|
[Press Release on the launch of HYSERVE-300 (in Japanese)] |
|
https://www.osakagas.co.jp/company/press/pr_2013/1206060_7831.html |
| [Corporate Profile] | |||
| Osaka Gas Co., Ltd. | |||
Head Office: |
4-1-2 Hiranocho, Chuo-ward, Osaka-city, Osaka |
||
Representative: |
Masataka Fujiwara (President & Representative Director) |
||
Amount of Capital: |
132,166,660,000 JPY |
||
Date of Establishment: |
April 10, 1897 |
||
Business Outline: |
Natural gas distribution and supply; power generation and supply, etc. |
||
| Daigas Gas and Power Solution Co., Ltd. | |||
Head Office: |
3-5- 11 Doshomachi, Chuo-ward, Osaka-city, Osaka |
||
Representative: |
Nobushige Goto (President & Representative Director) |
||
Amount of Capital: |
100,000,000 JPY |
||
Date of Establishment: |
October 1, 2019 |
||
Business Outline: |
Operation and maintenance of gas and power plants; power generation and supply; and engineering |
||
| Hyundai Rotem Company | |||
Head Office: |
37, Cheoldobangmulgwan-ro, Uiwang-si, Gyeonggi-do, 16082, Korea |
||
Representative: |
Yong-Bae, Lee (CEO) |
||
Amount of Capital: |
545,711,465,000 KRW |
||
Date of Establishment: |
July 1, 1977 |
||
Business Outline: |
Total railway systems supply, Ground weapon systems supply, Steel, automobile production and hydrogen infrastructures supply, etc. |
||
Contact Detail: |
Duseop Lee / duseop.lee@hyundai-rotem.co.kr / +82-10-2648-5039 |
||
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005489/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
